メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
水野 智博
臨床薬剤科
h-index
670
被引用数
15
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2009
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(63)
類似のプロファイル
(6)
フィンガープリント
Tomohiro Mizunoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Cisplatin
100%
Randomized Controlled Trial
72%
Acute Kidney Failure
65%
Histone
60%
Acute Lung Injury
60%
Adverse Drug Reaction
56%
Disease
54%
Injury
52%
Observational Study
43%
Polypharmacy
42%
Lung Cancer
40%
Combination Therapy
40%
Chemotherapy
37%
Nivolumab
36%
Sepsis
29%
Malignant Neoplasm
26%
Coronavirinae
24%
Nephrotoxicity
23%
Infection
22%
Chronic Kidney Failure
22%
Syndrome
21%
Retrospective Study
21%
Mouse
20%
Interstitial Lung Disease
20%
Immune Checkpoint Inhibitor
20%
Second-Line Chemotherapy
20%
Favipiravir
20%
Ascorbic Acid
20%
Anemia
20%
Breast Cancer
20%
Hyperuricemia
20%
Ureter Obstruction
20%
Transforming Growth Factor
20%
Thiamine
20%
Antianemic Agent
20%
Fluorouracil
20%
Chondroitin Sulfate
20%
Stomach Cancer
20%
Pharmacodynamics
20%
Antiinfective Agent
20%
Hydrocortisone
20%
Uric Acid
20%
Naldemedine
20%
Diffuse Large B Cell Lymphoma
20%
Immunoglobulin A Nephropathy
20%
Thrombocytopenia
20%
Febrile Neutropenia
20%
Self-Medication
20%
Tolerability
20%
Cholinergic Receptor Blocking Agent
20%
Keyphrases
Elderly Patients
40%
Risk Factors
32%
Disease Control
25%
Chemotherapy
24%
Cisplatin
24%
COVID-19
21%
Drug-induced Interstitial Lung Disease
20%
Favipiravir
20%
Second-line Chemotherapy
20%
Pharmaceutical Care
20%
Online Team-based Learning
20%
Japanese Adverse Drug Event Report (JADER)
20%
Early Dialysis
20%
Renal Hypoperfusion
20%
Pressure-induced
20%
Coagulation Pathway
20%
Steady State
20%
Hypoglycemic Therapy
20%
Hyperuricemia
20%
Outcome Prediction
20%
Severe Hypoalbuminemia
20%
5-fluorouracil (5-FU)
20%
COVID-19 Patients
20%
Sodium Zirconium Cyclosilicate
20%
HAT Therapy
20%
Cisplatin-induced Acute Kidney Injury
20%
Complement Activation
20%
Crry
20%
CD59
20%
Extracellular Histones
20%
Membrane Complement Regulators
20%
Small Group Learning
20%
Peritoneum
20%
Mixing Method
20%
Severe Acute Kidney Injury
20%
Age Mixing
20%
MRNA Vaccine
20%
Uric Acid
20%
Nocturnal Hypertension
20%
Telemonitoring System
20%
Blood Pressure Telemonitoring
20%
IgA Nephropathy (IgAN)
20%
Short-acting
20%
Febrile Neutropenia
20%
Diclofenac Sodium
20%
Tolerability
20%
Student Participation
20%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
20%
Colorectal Cancer
20%
Adjuvant Chemotherapy
20%
Medicine and Dentistry
Vasculotropin C
40%
Lymphangiogenesis
40%
Odds Ratio
25%
Disease
22%
Counseling
21%
Pharmaceutical Care
20%
Peritoneal Fibrosis
20%
Neutrophil
20%
Hospital-Acquired Pneumonia
20%
Ureter Obstruction
20%
Stomach Cancer
20%
Extracellular Trap
20%
End Stage Renal Disease
20%
Urothelial Cancer
20%
Sodium Zirconium Cyclosilicate
20%
Complement Regulator
20%
Peritoneum
20%
Complement Activation
20%
Lung Cancer
20%
Interstitial Lung Disease
20%
Thrombocytopenia
20%
Cisplatin
20%
Combination Therapy
20%
Drug Therapy
20%
Complement Component C5
20%
Naldemedine
20%
Randomized Clinical Trial
20%
Second-Line Chemotherapy
20%
Histone
20%
Acute Lung Injury
20%
Polypharmacy
20%
Lupus Nephritis
20%
Lipid Emulsion
20%
Immunoglobulin A Antibody
20%
Febuxostat
20%
Transforming Growth Factor
20%
Diabetic Nephropathy
20%
Senescence
20%
CD11b Antigen
20%
Nivolumab
20%
Cancer Chemotherapy
20%
Meta-Analysis
20%
Gemcitabine
20%
Liver Metastasis
20%
Adjuvant Chemotherapy
20%
Recurrent Disease
20%
Surgery
20%
Colorectal Carcinoma
20%
Mesothelial Cell
15%
Ultrafiltration
15%